Wohl & Fruchter LLP renewed its investigation into the fairness of Cross Country Healthcare’s proposed cash sale to Knox Lane at $13.25 per share. The renewed legal scrutiny adds deal-execution risk and may temper investor confidence in the transaction.
Wohl & Fruchter LLP renewed its investigation into the fairness of Cross Country Healthcare’s proposed cash sale to Knox Lane at $13.25 per share. The renewed legal scrutiny adds deal-execution risk and may temper investor confidence in the transaction.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.18
Ticker Sentiment
